Luoting Yu

4.2k total citations
141 papers, 2.9k citations indexed

About

Luoting Yu is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Luoting Yu has authored 141 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Molecular Biology, 37 papers in Organic Chemistry and 29 papers in Oncology. Recurrent topics in Luoting Yu's work include Epigenetics and DNA Methylation (20 papers), Synthesis and biological activity (19 papers) and Cancer-related gene regulation (17 papers). Luoting Yu is often cited by papers focused on Epigenetics and DNA Methylation (20 papers), Synthesis and biological activity (19 papers) and Cancer-related gene regulation (17 papers). Luoting Yu collaborates with scholars based in China, United States and Taiwan. Luoting Yu's co-authors include Tinghong Ye, Ningyu Wang, Yuquan Wei, Yongxia Zhu, Yong Xia, Xuejiao Song, Zhuo Tang, Zhihao Liu, Qian Lei and Fan Jiang and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Luoting Yu

135 papers receiving 2.9k citations

Peers

Countries citing papers authored by Luoting Yu

Since Specialization

Citations

This map shows the geographic impact of Luoting Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luoting Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luoting Yu more than expected).

Fields of papers citing papers by Luoting Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luoting Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luoting Yu. The network helps show where Luoting Yu may publish in the future.

Co-authorship network of co-authors of Luoting Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Luoting Yu. A scholar is included among the top collaborators of Luoting Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luoting Yu. Luoting Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2/4 degraders 2025 ·European Journal of Medicinal Chemistry ·(unknown), Wei Wei, Qi Zhang, Xin Chen, (unknown), (unknown), Yue Lin, Jia Gao, Ningyu Wang, Yu Cao, Luoting Yu, Zhihao Liu	1
2	An updated patent review of EZH2 inhibitors (2024–present) 2025 ·Expert Opinion on Therapeutic Patents ·(unknown), Siying Li, Qiang Tang, Hong Qiu, Qiangsheng Zhang, Luoting Yu	1
3	Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH 2024 ·Life Sciences ·Shuyan Zhou, Qiangsheng Zhang, (unknown), Yongxia Zhu, Xiang Hu, (unknown), Luoting Yu	3
4	A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy 2024 ·Biochemical Pharmacology ·Zhanzhan Feng, Wei Wei, Shirui Wang, (unknown), (unknown), (unknown), (unknown), Luoting Yu	2
5	Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6) 2024 ·Bioorganic Chemistry ·(unknown), Qiangsheng Zhang, Shuyan Zhou, (unknown), (unknown), (unknown), Qiang Feng, Luoting Yu	4
6	Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo 2023 ·Biochemical Pharmacology ·Yongxia Zhu, Lidan Zhang, Xuejiao Song, Qiangsheng Zhang, Ting Wang, (unknown), Luoting Yu	3
7	TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer 2023 ·Biochemical and Biophysical Research Communications ·Xiang Hu, (unknown), Sisi Li, Qiwei Wang, Yuerong Wang, (unknown), (unknown), Bo Yang, Luoting Yu, Zhihao Liu	6
8	Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis 2023 ·Microbiology Spectrum ·Xiang Wang, (unknown), (unknown), Zhiqun He, Xinyue Xu, (unknown), Fei Teng, (unknown), (unknown), Jumei Zeng, Luoting Yu, (unknown)	4
9	A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo 2022 ·Frontiers in Pharmacology ·Jun Zeng, (unknown), Xinyue Li, (unknown), Qiwei Wang, Jiangtao Ren, Rong Hu, (unknown), Zhihao Liu, Luoting Yu	2
10	Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4 2021 ·Bioorganic Chemistry ·Xiang Wang, Qiwei Wang, (unknown), Jing Ren, Yao Shi, Luoting Yu	14
11	Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·Ningyu Wang, Weiqiong Zuo, Rong Hu, Wanli Wang, Yongxia Zhu, Ying Xu, Luoting Yu, Zhihao Liu	4
12	Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis 2018 ·Cancer Letters ·Tiantao Gao, (unknown), Xi Hu, Qian Lei, Zhanzhan Feng, Xi Yu, Cuiting Peng, Xuejiao Song, (unknown), Ying Xu, Weiqiong Zuo, Jun Zeng, Zhihao Liu, Luoting Yu	32
13	Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis 2017 ·Cell Death and Disease ·Tinghong Ye, Fangfang Yang, Yongxia Zhu, Yali Li, Qian Lei, Xuejiao Song, Yong Xia, Ying Xiong, Lidan Zhang, Ningyu Wang, Lifeng Zhao, Hongfeng Gou, Yongmei Xie, Shengyong Yang, Luoting Yu, Li Yang, Yuquan Wei	76
14	Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion 2016 ·Biomedicine & Pharmacotherapy ·Tinghong Ye, (unknown), Yongxia Zhu, Qiang Feng, Bing He, (unknown), Lifeng Zhao, Yiwen Zhang, Luoting Yu, Li Yang	51
15	A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors 2016 ·Biomedicine & Pharmacotherapy ·Hongxia Deng, Jun Zeng, Yongxia Zhu, Tinghong Ye, Yong Xia, Yao Shi, Ningyu Wang, Lidan Zhang, Xuejiao Song, Weiqiong Zuo, Tiantao Gao, Luoting Yu	1
16	SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo 2014 ·Cancer Letters ·Yong Xia, Qian Lei, Yongxia Zhu, Tinghong Ye, Ningyu Wang, Guo‐Bo Li, (unknown), Yantong Liu, Bin Shao, Tao Yin, (unknown), Wenshuang Wu, Xuejiao Song, Ying Xiong, Yuquan Wei, Luoting Yu	35
17	A Novel Benzothiazole Derivative YLT322 Induces Apoptosis via the Mitochondrial Apoptosis Pathway In Vitro with Anti-Tumor Activity in Solid Malignancies 2013 ·PLoS ONE ·Xuejiao Song, Yong Xia, (unknown), Lidan Zhang, (unknown), Youzhi Xu, Tinghong Ye, Yao Shi, (unknown), Luoting Yu	22
18	Organocatalytic asymmetric Michael reaction with acylsilane donors 2012 ·Organic & Biomolecular Chemistry ·Lei Wu, Guangxun Li, Qingquan Fu, Luoting Yu, Zhuo Tang	19
19	Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway in vitro and inhibits tumor growth in vivo 2011 ·Cancer Letters ·Youzhi Xu, Renlin Zheng, Yan Zhou, Feng Peng, Hongjun Lin, Qian Bu, Yong-Qiu Mao, Luoting Yu, Yang Li, Shengyong Yang, Yinglan Zhao	19
20	Ethyl 3-amino-4H-thieno[2,3-b]pyridine-2-carboxylate 2008 ·Acta Crystallographica Section E Structure Reports Online ·Renlin Zheng, Wenqin Zhang, Luoting Yu, Shengyong Yang, Li Yang	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact